Kite Pharma, Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 2
Founded: Santa Monica CA United States (2009)
Status: Acquired by Gilead Sciences (2017)

Organization Overview

First Clinical Trial
2015
NCT02348216
First Marketed Drug
2017
axicabtagene ciloleucel (Yescarta)
First NDA Approval
2017
axicabtagene ciloleucel (Yescarta)
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Kite Systems